In this issue:
SARS-CoV-2 infection and psoriasis course
Biologic use and risk of serious infection in patients with psoriasis
Biologic effects on imaging and biomarkers of CVD
Secukinumab in paediatric patients with moderate-to-severe plaque psoriasis
Biologic treatment for psoriasis in cancer patients
Failure of biologic therapy in psoriasis
Impact of BMI on the efficacy of biological therapies
Predictors of biologic agent switch in psoriasis
Rituximab for antineutrophil cytoplasm antibody-associated vasculitis
Please login below to download this issue (PDF)